#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Real-world data on the efficacy and safety of ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia, a single-centre experience


Authors: F. Farkaš 1;  M. Hrubiško 1,2;  A. Bátorová 1
Authors‘ workplace: Klinika hematológie a transfúziológie LF UK, SZU a UNB, Bratislava, SR 1;  Katedra hematológie a transfúziológie LF SZU, Bratislava, SR 2
Published in: Transfuze Hematol. dnes,28, 2022, No. 2, p. 94-99.
Category: Original Papers
doi: https://doi.org/10.48095/cctahd2022prolekare.cz8

Overview

Introduction: Treatment of chronic lymphocytic leukaemia (CLL) continues to develop dramatically. Chemoimmunotherapy that historically represented the golden standard of treatment has been largely replaced by molecular-targeted therapies that are more effective and safer. Objective: A retrospective study to evaluate the efficacy and safety of innovative „chemo-free“ therapy (ibrutinib and venetoclax) in patients with CLL. Material and methods: from January 2016 to September 2021, 83 patients with chronic lymphocytic leukaemia treated in our institute were included in the study. A total of 63 patients received ibrutinib (15.9% in front-line setting) and 20 patients received venetoclax +/– rituximab (85% as monotherapy and 5% in front-line setting). The median age was 64 years (range 39–81 years). Each group had a median of two prior lines of therapy (range 1–6). The median follow-up was 31 months for ibrutinib and 23 months for venetoclax. Results: the majority of patients responded to treatment with an overall response rate (ORR) of 92% for ibrutinib and 90% for venetoclax. The rate of complete remission was higher with venetoclax (relative risk – RR = 2.02, 95% CI: 1.16–3.5; P = 0.012). The 3-year progression-free survival (PFS) and overall survival (OS) were 82% and 83% for ibrutinib, 80% and 80% for venetoclax respectively. The majority of side effects reported were relatively mild to moderate. Conclusion: In our study, we demonstrate that novel agents, ibrutinib and venetoclax provide comparable results in patients with CLL treated outside clinical trials.

Keywords:

Safety – ibrutinib – venetoclax – chronic lymphocytic leukaemia – efficacy


Sources

1. Patel K, Pagel JM. Current and future treatment strategies in chronic lymphocytic leukemia. J Hematol Oncol. 2021; 14: 69: 1–20.

2. Hallek M. Chronic lymphocytic leukemia: 2020 update on dia­gnosis, risk stratification and treatment. Am J Hematol. 2019; 94: 1266–1287.

3. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for dia­gnosis, treatment and follow-up. Ann Oncol. 2020; 32: 23–33.

4. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011; 117: 6287–6296.

5. Molica S, Giannarelli D, Baumann T, et al. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis. Eur J Haematol. 2020; 104: 512–515.

6. Dreger P, Ghia P, Schetelig J, et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood. 2018; 132: 892–902.

7. Byrd JC, Brown JR, O‘Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371: 213–223.

8. Munir T, Brown JR, Brien SO, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019; 94 (12): 1353–1363.

9. Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20: 43–56.

10. Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018; 103 (5):  874–879.

11. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370 (11): 997–1007.

12. Eyre TA, Kirkwood AA, Gohill S, et al. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. Br J Haematol. 2019; 185 (4): 656–669.

13. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016; 17: 768–778.

14. Mato AR, Thompson M, Allan JN, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018; 103 (9): 1511–1517.

15. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018; 378: 1107–1120.

16. Eyre TA, Lamanna N, Roeker LE, et al. Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia. Haematologica. 2021; 106 (1): 284–287.

17. Mato AR, Hill BT, Lamanna N, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multi-center study of 683 patients. Ann Oncol. 2017; 28 (5): 1050–1056.

18. Moreno C. Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. Hematology Am Soc Hematol Educ Program. 2020; (1): 33–40.

19. Kwok M, Rawstron AC, Varghese A, et al. Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 2016; 128: 2770–2773.

Labels
Haematology Internal medicine Clinical oncology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#